Back to search results

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia (AML)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749

  • Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749

  • Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749

  • Memorial Sloan Kettering Suffolk-Commack, Commack, New York, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749

  • Memorial Sloan Kettering Westchester, Harrison, New York, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749
    Contact: Principal Investigator (Eytan Stein, MD)

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749
    Contact: Study coordinator (Aaron Goldberg, MD, Phd) · 646-608-3752

  • Memorial Sloan Kettering Nassau, Uniondale, New York, United States

    Contact: Study coordinator (Eytan Stein, MD) · 646-608-3749
Study leads

  • Eytan Stein, MD

    Principal Investigator

    Memorial Sloan Kettering Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)